|
⚲
|
| Keyboard |
| Commodore Capital LP
✚
|
|
|---|---|
| CRD # | 304370 |
| SEC # | 801-117168 |
| CIK # | 0001831942 |
| AUM | 2,369.3 M (2026-03-31) |
| Employees | 12 (50% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-256-8600 |
| Address | 444 Madison Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Relay Therapeutics Inc | 0.2 | ||
| Alkermes PLC | 0.1 | ||
| Imara Inc | 0.1 | ||
| UNUM Therapeutics Inc | 0.1 | ||
| Aeglea Biotherapeutics Inc | 0.1 | ||
| TYRA Biosciences Inc | 0.1 | ||
| Celldex Therapeutics Inc | 0.1 | ||
| Nuvalent Inc | 0.1 | ||
| Amylyx Pharmaceuticals Inc | 0.1 | ||
| Kymera Therapeutics Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Commodore Capital Master LP | [2019-07-15] | 891.5 M | 2,369.3 M |
| Filed 2026-02-25 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $10,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 2.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 2.4 |
| By Discretionary | ||
| Discretionary | 3 | 2.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 2.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.7 | |
| United States Persons | 1.6 | |
| Total | 3 | 2.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Commodore Capital LP | Executive Officer | 2 | 2 | |
| Michael Kramarz | Executive Officer | 2 | 2 | |
| Egen Atkinson | Executive Officer | 2 | 2 | |
| Commodore Capital Domestic GP LP | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001831942] | |
| 3 | [0001831942] | |
| 4 | [0001831942] | |
| SC 13G | [0001831942] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300729275T4UVFT94 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Vera Therapeutics Inc | |
| Commodore Capital LP | |
| Vistagen Therapeutics Inc | |
| Enliven Therapeutics Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Vera Therapeutics Inc VERA
Class A Common Stock
|
2024-01-10 | Sell | 1,050,000 | $18.00 | 18,900,000 |
|
Vistagen Therapeutics Inc VTGN
Pre-Funded Warrants (Right to Buy) · derivative
|
2023-10-04 | Grant | 2,788,620 | ||
|
Vistagen Therapeutics Inc VTGN
Tranche 1 Warrants (Right to Buy) · derivative
|
2023-10-04 | Grant | 1,394,310 | ||
|
Vistagen Therapeutics Inc VTGN
Tranche 2 Warrants (Right to Buy) · derivative
|
2023-10-04 | Grant | 1,690,014 | ||
|
Vistagen Therapeutics Inc VTGN
Common Stock
|
2023-08-07 | Buy | 775,756 | $23.15 | 17,958,751 |
|
Vera Therapeutics Inc VERA
Class A Common Stock
|
2023-06-20 | Buy | 448,217 | $15.17 | 6,799,452 |
|
Enliven Therapeutics Inc ELVN
Common stock, par value $0.001 per share
|
2023-02-23 | Other | 729,891 | ||
|
Enliven Therapeutics Inc ELVN
Common stock, par value $0.001 per share
|
2023-02-23 | Buy | 621.75 | $22.07 | 13,722 |
|
Enliven Therapeutics Inc IMRA
Common stock, par value $0.001 per share
|
2023-02-22 | Buy | 23,565 | $5.11 | 120,417 |
|
Enliven Therapeutics Inc IMRA
Common stock, par value $0.001 per share
|
2023-02-21 | Buy | 8,194 | $5.25 | 43,018 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2022-11-14 | Sell | 3,250,000 | $0.71 | 2,307,500 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-24 | Buy | 2,922 | $5.42 | 15,837 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-22 | Buy | 9,979 | $5.49 | 54,785 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-19 | Buy | 3,225 | $5.44 | 17,544 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-11 | Buy | 7,941 | $6.05 | 48,043 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-10 | Buy | 9,622 | $5.85 | 56,289 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-08 | Buy | 560 | $5.99 | 3,354 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-05 | Buy | 7,800 | $5.95 | 46,410 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-04 | Buy | 1,400 | $5.88 | 8,232 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-02 | Buy | 8,880 | $5.64 | 50,083 |
| showing 20 of 29 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Alatus Capital LLC
✚
|
2,398.4 M | |
|
Heard Capital LLC
✚
|
IL | 2,395.9 M |
|
Ram Active Investments Sa
✚
|
2,393.2 M | |
|
Nordflint Capital Partners Fondsmaeglerselskab A/S
✚
|
2,392.2 M | |
|
Mudita Advisors LLP
✚
|
2,383.3 M | |
|
Cartenna Capital LP
✚
|
CT | 2,359.2 M |
|
AFBI LP
✚
|
FL | 2,342.4 M |
|
Actusraypartners Limited
✚
|
2,339.2 M | |
|
ISAM Funds UK Limited
✚
|
2,333.7 M | |
|
ISAM Funds USA LLC
✚
|
FL | 2,333.7 M |